Many Japanese Scientists’ Jobs at Risk from Labor Law Loophole

Universities and institutes are preparing to terminate thousands of technically temporary researchers by next spring instead of granting them the permanent employment mandated by a 2013 labor law.

Written byDan Robitzski
| 2 min read
Street view of an office building partially obscured by green trees
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Scientists nearing their 10-year work anniversaries at Japanese universities and institutes find themselves in a difficult position, as their employers are preparing to lay them off instead of offering them the permanent employment promised to them by a 2013 labor law, Science and Nature report.

Over the past 30 years, the Japanese government sought to bolster its scientific research programs, especially at government-funded institutes like RIKEN, but ran into roadblocks due to apprehension over adding a significant number of permanent employees to the federal payroll, Science reports. Instead, many scientists were hired with what’s called a fixed-term contract, which treated them as temporary, with lesser benefits and lower salaries than they’d earn under long-term employment.

A 2013 labor law guaranteed workers on fixed-term contracts the right to request permanent employment after five years on the job, according to Nature, although that was later extended to 10 years for many researchers. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies